A once-daily GLP-1 receptor agonist approved for both type 2 diabetes and obesity management with demonstrated cardiovascular mortality reduction.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Liraglutide is a once-daily injectable glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk and approved by the FDA for two distinct clinical indications under two separate brand names: Victoza for the management of type 2 diabetes mellitus, and Saxenda for chronic weight management in adults with obesity or overweight accompanied by at least one weight-related comorbidity. It was first approved for diabetes in 2010, with the obesity indication following in 2014, making it one of the most extensively studied peptide-based therapeutics in modern endocrinology.
At the molecular level, liraglutide is a 26-amino-acid analogue of native human GLP-1 that shares 97% sequence homology with the endogenous hormone. The critical structural difference that separates it from a short-lived native peptide is a C-16 palmitoyl fatty acid chain attached via a glutamic acid spacer to lysine at position 26. This modification enables reversible, non-covalent binding to circulating serum albumin, which dramatically extends the compound’s half-life from the roughly two minutes of endogenous GLP-1 to approximately thirteen hours — long enough to support once-daily subcutaneous dosing. The albumin binding also slows renal filtration and protects the peptide from dipeptidyl peptidase-4 (DPP-4) enzymatic degradation at the N-terminus.
The commercial success and therapeutic versatility of liraglutide helped establish GLP-1 receptor agonism as one of the most consequential pharmacological mechanisms in contemporary medicine. Its clinical track record spans more than a decade of real-world use, hundreds of randomized controlled trials, and the landmark LEADER cardiovascular outcomes trial, which demonstrated meaningful reductions in major adverse cardiovascular events in high-risk type 2 diabetes patients. As the field has evolved toward longer-acting agents like semaglutide and dual-agonist compounds, liraglutide’s extensive data set remains a foundational reference point. For researchers and clinicians navigating the GLP-1 landscape, understanding how liraglutide works, what its evidence base actually shows, and where its limitations lie is essential context for evaluating the entire therapeutic class.
This resource is intended for educational and research purposes. If you are considering any GLP-1 agent therapeutically, work directly with a licensed clinician who can evaluate your individual metabolic profile. You can also explore dosing considerations using our peptide calculators or get a deeper breakdown of mechanisms through the AI Coach.
Liraglutide exerts its primary metabolic effects by binding with high affinity to the glucagon-like peptide-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed widely in pancreatic islets, the gastrointestinal tract, the kidney, the heart, and the central nervous system. When liraglutide docks with the GLP-1R on pancreatic beta cells, it activates adenylyl cyclase through the Gs signaling pathway, elevating intracellular cyclic AMP (cAMP). This cAMP surge activates protein kinase A (PKA) and the exchange protein directly activated by cAMP 2 (Epac2), both of which potentiate glucose-stimulated insulin secretion by sensitizing the secretory machinery to calcium influx. Crucially, this entire cascade is conditioned on ambient glucose concentration — liraglutide does not trigger insulin release when blood glucose is normal or low, which is why GLP-1 receptor agonists carry minimal intrinsic hypoglycemia risk. On pancreatic alpha cells, liraglutide suppresses glucagon secretion through a combination of direct GLP-1R-mediated paracrine inhibition and indirect effects mediated through elevated local insulin levels, reducing hepatic glucose output during the post-prandial period.
A substantial component of liraglutide’s therapeutic effect — particularly its weight-loss action at the 3.0 mg Saxenda dose — is mediated through direct action on the central nervous system. GLP-1 receptors are densely expressed in the hypothalamic arcuate nucleus, where liraglutide activates pro-opiomelanocortin (POMC) neurons and inhibits neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons, shifting the hypothalamic setpoint toward reduced energy intake. Liraglutide also activates GLP-1Rs in the brainstem, particularly the nucleus tractus solitarius (NTS), which integrates peripheral satiety signals from vagal afferents. Peripheral GLP-1R stimulation in the gut and vagus nerve synergizes with these central effects to produce robust, meal-independent reductions in appetite and food-seeking behavior. Simultaneously, liraglutide slows gastric emptying by reducing the rate at which the stomach releases nutrient content into the duodenum, flattening post-meal glucose and insulin peaks and extending the subjective sensation of fullness after eating. The combination of central appetite suppression and peripheral gastric slowing is mechanistically distinct from earlier weight-loss drugs, which relied primarily on either monoamine signaling or fat absorption inhibition.
The cardiovascular benefit observed in LEADER cannot be fully explained by glucose lowering or weight reduction alone. Direct GLP-1R signaling in cardiac myocytes and endothelial cells is thought to contribute through multiple pathways: improved left ventricular function, reduced ischemia-reperfusion injury, favorable effects on endothelial nitric oxide synthase (eNOS) activity, and attenuation of inflammatory cytokine signaling through NF-kB inhibition. Liraglutide appears to reduce atherosclerotic plaque progression in animal models partly by decreasing macrophage foam cell formation and reducing oxidative stress within the arterial wall. In the kidney, GLP-1R activation reduces afferent arteriolar tone and blunts the renin-angiotensin-aldosterone system, potentially explaining the albuminuria reductions seen in LEADER. Anti-inflammatory effects mediated through GLP-1R on immune cells — including monocytes and macrophages — may provide an additional layer of protection in tissues chronically exposed to metabolic stress. These pleiotropic cardiovascular and renal actions are an active area of mechanistic research and help explain why the GLP-1 receptor has emerged as one of the most therapeutically compelling targets in cardiometabolic medicine.
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial stands as the most consequential evidence supporting liraglutide’s use in high-cardiovascular-risk patients with type 2 diabetes. Enrolling 9,340 patients across 32 countries with a median follow-up of 3.8 years, LEADER was designed as a superiority trial after FDA mandates required all new diabetes drugs to demonstrate cardiovascular safety. The primary outcome — a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke — occurred in 13.0% of liraglutide-treated participants versus 14.9% in the placebo group, a statistically significant hazard ratio of 0.87 (95% CI 0.78–0.97). The benefit was driven particularly by a significant reduction in cardiovascular death (HR 0.78), which is notable because most subsequent CVOT trials with GLP-1 agents have shown stronger effects on non-fatal events. All-cause mortality was also reduced (HR 0.85). The renal composite endpoint — new or worsening nephropathy — was reduced by 22%. LEADER fundamentally shifted the clinical positioning of liraglutide from a glucose-lowering drug to a cardiometabolic protective agent, influencing prescribing guidelines worldwide and providing a template for subsequent cardiovascular trials with semaglutide and newer agents.
The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence in Nondiabetic and Diabetic Individuals) program was a suite of Phase 3 trials designed to evaluate liraglutide 3.0 mg specifically for weight management. The flagship SCALE Obesity and Prediabetes trial enrolled 3,731 non-diabetic adults with a BMI of 30 or above (or 27 with a comorbidity) and randomized them to liraglutide 3.0 mg or placebo alongside lifestyle counseling for 56 weeks. Mean weight loss was 8.4 kg (approximately 8%) in the liraglutide group versus 2.8 kg (approximately 2.6%) in the placebo group. The proportion achieving 5% or greater weight loss was 63.2% with liraglutide versus 27.1% with placebo; 33.1% versus 10.6% achieved 10% or greater weight loss. Among participants with prediabetes at baseline, conversion to type 2 diabetes was significantly lower in the liraglutide group over a three-year observation period, suggesting meaningful disease-modifying potential beyond simple weight reduction. The SCALE Diabetes trial demonstrated that liraglutide 3.0 mg outperformed the 1.8 mg diabetes dose and placebo for weight loss in patients who already had type 2 diabetes, while maintaining glycemic benefit — an important finding for clinicians managing overweight patients with both conditions simultaneously.
As semaglutide (both subcutaneous weekly Ozempic/Wegovy and oral Rybelsus) has come to dominate clinical and media attention, a natural question arises: how does liraglutide compare? The SUSTAIN trials and STEP program have consistently shown semaglutide producing roughly 1.5 to 2 times the weight loss of liraglutide at comparable durations. In head-to-head comparisons (SUSTAIN 10), subcutaneous semaglutide 1.0 mg once weekly produced greater reductions in HbA1c and body weight than liraglutide 1.2 mg once daily. Wegovy (semaglutide 2.4 mg weekly) achieved mean weight loss of approximately 15% in the STEP 1 trial, nearly double the Saxenda effect. The structural reasons for this potency gap relate to semaglutide’s albumin-binding modification that confers a full seven-day half-life and possibly greater CNS penetrance. However, liraglutide retains meaningful advantages in specific contexts: its shorter half-life allows faster wash-out in cases of intolerance or adverse events, its once-daily kinetics may suit some patients’ adherence patterns, and its longer post-marketing safety record provides clinicians with high confidence in long-term risk profiles that semaglutide is still accumulating.
While liraglutide was not developed primarily as a liver-directed therapy, accumulating evidence supports meaningful hepatic benefits that are now being more deliberately targeted by next-generation dual agonists. The LEAN trial — a Phase 2 randomized controlled study — evaluated liraglutide 1.8 mg in 52 patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). After 48 weeks, 39% of liraglutide-treated patients achieved resolution of NASH on follow-up biopsy, compared to 9% of placebo-treated patients (p=0.019). Importantly, none of the liraglutide-treated patients showed progression of liver fibrosis during the trial period, compared to 9% progression in the placebo group. Mechanistically, the hepatic benefit likely reflects a combination of reduced caloric intake and weight loss, improved insulin sensitivity reducing lipogenesis, and potentially direct GLP-1R effects on hepatocytes and Kupffer cells reducing inflammatory signaling. These LEAN trial findings, while preliminary given the small sample size, helped motivate the development of dual glucagon/GLP-1 receptor agonists like survodutide that are now in advanced trials for metabolic dysfunction-associated steatohepatitis (MASH).
The FDA approved liraglutide (Saxenda) for weight management in adolescents aged 12 to 17 years with obesity in 2020, making it the first GLP-1 receptor agonist approved in a pediatric population. The pivotal trial enrolled 251 adolescents with a BMI at or above the 95th percentile for age and sex and randomized them to liraglutide 3.0 mg or placebo alongside behavioral intervention for 56 weeks. In the liraglutide group, 43.3% achieved a 5% or greater reduction in BMI standard deviation score versus 18.7% in the placebo group. Total body weight outcomes were complicated by ongoing growth, but the improvements in cardiometabolic risk markers — including waist circumference, blood pressure, and lipid profiles — were clinically meaningful. The tolerability profile in adolescents mirrored that in adults, with nausea and vomiting representing the most common adverse events leading to discontinuation. This pediatric approval has important public health implications given the rising prevalence of obesity-related type 2 diabetes and metabolic syndrome in younger populations, though the long-term cardiovascular and metabolic benefits in this age group remain to be established through follow-up research.
Liraglutide is administered via subcutaneous injection once daily at any consistent time of day, independent of meals. To minimize gastrointestinal side effects — which are primarily nausea and vomiting in the early weeks of use — clinical guidelines universally recommend a gradual dose titration protocol. For the Victoza (diabetes) indication, the recommended starting dose is 0.6 mg once daily for one week, followed by escalation to 1.2 mg daily. If further glycemic control is needed after at least one week at 1.2 mg, the dose may be increased to 1.8 mg daily, which represents the maximum approved diabetes dose. For the Saxenda (obesity) indication, the titration schedule is more gradual: 0.6 mg weekly for four weeks, followed by weekly 0.6 mg increments up to the target dose of 3.0 mg daily. If patients cannot tolerate a particular dose level after additional time, up-titration should be paused or the dose reduced. There is no therapeutic benefit from doses above 3.0 mg/day, and the compound is not dose-escalated beyond this ceiling. For reference and calculation support, explore our peptide dosing calculators.
Liraglutide is supplied in a multi-dose prefilled pen device containing 18 mg/3 mL (6 mg/mL). Each pen delivers doses across the full dose range with a built-in dose selector. Approved injection sites are the abdomen, upper arm, or thigh; systematic rotation within and between sites is recommended to prevent lipohypertrophy — localized fatty tissue buildup at frequently injected areas that can impair absorption consistency. The pen should be stored refrigerated (2–8°C) before first use; once in use, it can be kept at room temperature (up to 30°C) or refrigerated for up to 30 days. Needles are not supplied with the device and must be purchased separately; 4–6 mm pen needles are appropriate for most patients. The injection should be delivered subcutaneously — not intramuscularly or intravenously. If a daily dose is missed and the next scheduled dose is more than 12 hours away, the missed dose should be taken at the earliest convenience; if less than 12 hours remain, the missed dose should be skipped entirely to avoid double dosing.
Liraglutide does not require dose adjustment in patients with mild-to-moderate renal impairment or mild hepatic impairment, though caution is warranted in severe renal or hepatic dysfunction due to limited clinical data in these populations. Use in type 1 diabetes is not approved and is not supported by evidence. Liraglutide is contraindicated in patients or their first-degree relatives with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), owing to rodent carcinogenicity data, though the relevance of this finding to human risk remains uncertain based on current evidence. The compound is classified as FDA Pregnancy Category C and should be discontinued before a planned pregnancy or as soon as pregnancy is detected. Drug interactions are primarily pharmacokinetic: liraglutide’s effect on gastric emptying can reduce the rate of absorption of orally co-administered medications; drugs with narrow therapeutic windows dependent on rapid absorption should be taken under careful monitoring or dosed at a consistent interval relative to liraglutide injection.
Outside of the approved clinical indications, liraglutide has been studied at the approved dose ranges (1.2–3.0 mg/day) in research settings examining NAFLD/NASH, polycystic ovary syndrome (PCOS), obstructive sleep apnea, and neurodegenerative disease. None of these represent approved uses. Researchers in preclinical settings sometimes use liraglutide as a comparator compound for novel GLP-1 analogs or dual agonists, leveraging its extensive characterization as a reference point. Any research administration must be conducted under appropriate institutional oversight and ethical approval. For individuals exploring liraglutide-related topics further, the Peptide Database contains comparison data across GLP-1 class compounds, and the AI Coach can help contextualize research protocols.
The most frequently reported adverse effects of liraglutide are gastrointestinal in nature and are directly tied to the drug’s pharmacological mechanisms — slowed gastric emptying and central appetite suppression. Nausea is the most common complaint, reported in approximately 20–40% of patients in clinical trials, and tends to be most pronounced during the initial dose titration phase. Vomiting, diarrhea, constipation, and dyspepsia are also common, particularly in the first four to eight weeks of treatment. For the majority of patients, these symptoms are dose-dependent, transient, and manageable through the structured titration protocol described above. Eating smaller, lower-fat meals during the initiation phase, avoiding eating past the point of fullness, and taking liraglutide at a time that minimizes nausea disruption (e.g., before bed for patients who experience morning nausea) can significantly improve tolerability. Approximately 7–10% of participants in SCALE trials discontinued liraglutide due to gastrointestinal adverse events — a rate that should be considered when counseling patients who express concerns about tolerability.
Pancreatitis is a serious adverse event that has been a focus of regulatory and clinical concern across the GLP-1 receptor agonist class. The risk appears to be low but real: liraglutide’s FDA prescribing information includes a warning about acute pancreatitis, and the compound should be discontinued if pancreatitis is suspected. However, large-scale CVOT data and meta-analyses have not demonstrated a statistically significant elevation in pancreatitis risk compared to other diabetes therapies, and patients with a prior history of pancreatitis are excluded from liraglutide use as a precautionary measure. Cholelithiasis (gallstone formation) has been reported at modestly elevated rates with GLP-1 receptor agonists, consistent with the class-wide observation that rapid weight loss increases biliary cholesterol saturation. The aforementioned medullary thyroid carcinoma concern — derived from rat and mouse models showing C-cell hyperplasia at supratherapeutic doses — carries a black box warning, though epidemiological surveillance has not established excess MTC risk in the human population to date. Rare case reports of acute kidney injury (typically secondary to severe dehydration from vomiting and diarrhea) and hypersensitivity reactions including anaphylaxis have been documented.
Given its approval history dating to 2010, liraglutide has one of the longest real-world safety track records among GLP-1 receptor agonists. Long-term LEADER follow-up data (up to five years for some participants) showed no unexpected serious safety signals beyond those identified in earlier trials. Routine monitoring for patients on liraglutide should include periodic assessment of glycemic parameters (HbA1c, fasting glucose), renal function, liver enzymes if hepatic disease is present, and body weight. Heart rate elevation — a class effect of GLP-1 receptor agonists — averages approximately 2–3 bpm with liraglutide and should be factored into risk assessment in patients with underlying arrhythmia or heart failure. Suicidal ideation has been listed as a consideration in the Saxenda prescribing information following a class-wide regulatory review, though causality has not been established; clinicians should enquire about mood changes during the weight-management use of the agent. The overall benefit-risk profile of liraglutide, as reflected in its FDA approval and continued clinical use across millions of patients globally, remains favorable when used in appropriately selected populations under medical supervision.
Both Victoza and Saxenda contain liraglutide as the active ingredient and use the same molecular compound — the difference is entirely in the approved indication and dose. Victoza is approved for type 2 diabetes management and is used at doses of 1.2 mg or 1.8 mg once daily. Saxenda is approved for chronic weight management and is titrated up to 3.0 mg once daily. The higher obesity dose was found to produce greater weight loss than the diabetes dose, which is why a separate approval was sought for the weight indication. The two products use the same prefilled pen device but come in different pack configurations. They are not interchangeable for insurance or prescribing purposes.
Semaglutide — sold as Wegovy at 2.4 mg weekly for obesity — consistently produces approximately double the weight loss of liraglutide 3.0 mg daily in head-to-head comparisons. STEP trials showed mean weight loss of around 15% with semaglutide versus approximately 8% with liraglutide in similar populations. The structural advantage of semaglutide is its longer half-life (seven days versus thirteen hours) and potentially greater central nervous system penetrance. For patients who cannot tolerate semaglutide or who require a shorter wash-out period, liraglutide remains a clinically useful alternative with an extensive safety record.
Liraglutide is not approved for type 1 diabetes, and its use in this population is not supported by strong evidence. Patients with type 1 diabetes do not have functional beta cells, so the glucose-dependent insulin secretion mechanism — a primary therapeutic lever — does not apply. Some research has explored potential benefits related to weight reduction and insulin dose reduction in type 1 patients, but the cardiovascular and glycemic evidence base that supports use in type 2 diabetes does not extend to type 1. Use in type 1 diabetes should be considered investigational and is not recommended outside of formally supervised research settings.
Liraglutide carries a black box warning for medullary thyroid carcinoma based on studies in rodents showing thyroid C-cell hyperplasia at supratherapeutic doses. However, GLP-1 receptors are expressed on C-cells in rodents at much higher density than in humans, and the clinical relevance of this rodent finding to human thyroid cancer risk remains uncertain. Human epidemiological data and post-marketing surveillance have not established a causal link between liraglutide use and MTC in people. The drug is contraindicated in patients with a personal or family history of MTC or MEN2 as a precautionary measure. Regular thyroid monitoring is not required for patients without these risk factors, but any new neck mass or symptoms of thyroid disease should be evaluated promptly.
Glycemic effects — particularly improvements in post-meal glucose — begin within the first week of treatment at even the starting 0.6 mg dose. Meaningful HbA1c reduction typically becomes apparent after 4–8 weeks of use at therapeutic dose. Weight loss effects are generally more gradual; most patients begin noticing appetite suppression within the first two weeks, but clinically meaningful weight reduction (5% or more) typically requires 12–24 weeks at the full 3.0 mg dose. The structured titration schedule means most patients are not at full therapeutic dose until week 5. Individual variability in response is substantial, and some patients are non-responders — a practical consideration for deciding whether to continue therapy at the 16-week mark.
Discontinuation of liraglutide typically leads to gradual weight regain and return of pre-treatment glycemic parameters, reflecting the drug’s mechanism of action rather than any disease-modifying effect that persists after cessation. Studies examining cessation of GLP-1 receptor agonists consistently show that most of the weight lost during treatment is regained within 12 months of stopping, underscoring that these medications address but do not cure the underlying physiological drivers of obesity and metabolic disease. This trajectory is important for patient counseling and for framing the treatment as chronic disease management rather than a time-limited course.
Liraglutide does not require dose adjustment for mild-to-moderate chronic kidney disease (CKD stages 1–3) and has shown renal-protective signals in LEADER trial secondary analyses. However, the primary safety concern in patients with CKD is the risk of acute kidney injury secondary to dehydration from gastrointestinal adverse effects — vomiting and diarrhea — particularly during the titration phase. In patients with severe renal impairment (eGFR below 30 mL/min/1.73m²) or end-stage renal disease, liraglutide’s use carries greater uncertainty due to limited clinical data in these populations. The FLOW trial with semaglutide — which showed significant renal protection — is generating interest in the renal applications of GLP-1 receptor agonists more broadly, though liraglutide-specific renal outcome data remains a secondary endpoint analysis rather than a primary finding.
The cardiovascular benefit seen in LEADER is thought to be mediated through multiple overlapping mechanisms: direct GLP-1R signaling in the heart and vasculature improving endothelial function and reducing inflammation, anti-atherosclerotic effects reducing plaque vulnerability, favorable changes in traditional risk factors (weight, blood pressure, lipids), and possible reductions in ischemia-reperfusion injury. Importantly, the cardiovascular benefit in LEADER appears early — within the first year — and precedes the full glycemic and weight loss benefit, suggesting a direct vascular mechanism that is not simply a downstream consequence of metabolic improvement. This pattern of early cardiovascular protection has since been observed with other GLP-1 agents and is an active focus of basic science research.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.